BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $31,100 | -23.4% | 824,068 | -7.5% | 0.07% | -20.4% |
Q2 2023 | $40,587 | +43.5% | 890,839 | +27.8% | 0.09% | +34.8% |
Q1 2023 | $28,278 | -61.7% | 697,189 | -51.9% | 0.07% | -63.9% |
Q4 2022 | $73,843 | -99.9% | 1,448,750 | +44.0% | 0.19% | +28.2% |
Q3 2022 | $54,175,000 | -37.9% | 1,005,852 | -26.0% | 0.15% | -36.1% |
Q2 2022 | $87,307,000 | +151.6% | 1,359,276 | +203.7% | 0.23% | +242.6% |
Q1 2022 | $34,705,000 | -1.7% | 447,585 | +8.8% | 0.07% | 0.0% |
Q4 2021 | $35,313,000 | +35.4% | 411,389 | +26.9% | 0.07% | +28.3% |
Q3 2021 | $26,073,000 | +43.7% | 324,155 | +43.9% | 0.05% | +43.2% |
Q2 2021 | $18,139,000 | +201.9% | 225,341 | +216.3% | 0.04% | +184.6% |
Q1 2021 | $6,009,000 | -23.4% | 71,243 | -27.2% | 0.01% | -27.8% |
Q4 2020 | $7,848,000 | -44.2% | 97,808 | -44.1% | 0.02% | -52.6% |
Q3 2020 | $14,064,000 | +70.5% | 174,874 | +82.1% | 0.04% | +52.0% |
Q2 2020 | $8,249,000 | +5.9% | 96,006 | +0.1% | 0.02% | -10.7% |
Q1 2020 | $7,788,000 | -6.5% | 95,943 | -3.7% | 0.03% | +16.7% |
Q4 2019 | $8,332,000 | -57.5% | 99,640 | -55.5% | 0.02% | -60.7% |
Q3 2019 | $19,599,000 | +7.7% | 224,063 | +0.9% | 0.06% | +10.9% |
Q2 2019 | $18,192,000 | -39.4% | 222,129 | -39.8% | 0.06% | -42.1% |
Q1 2019 | $30,026,000 | -9.7% | 369,282 | -26.8% | 0.10% | -20.8% |
Q4 2018 | $33,252,000 | -9.7% | 504,758 | +5.7% | 0.12% | +4.3% |
Q3 2018 | $36,811,000 | +2030.3% | 477,503 | +1939.7% | 0.12% | +1816.7% |
Q2 2018 | $1,728,000 | +27.0% | 23,411 | +11.9% | 0.01% | +20.0% |
Q1 2018 | $1,361,000 | +3.9% | 20,920 | +3.2% | 0.01% | +25.0% |
Q4 2017 | $1,310,000 | +0.4% | 20,273 | -2.5% | 0.00% | -20.0% |
Q3 2017 | $1,305,000 | +15.6% | 20,797 | +11.5% | 0.01% | 0.0% |
Q2 2017 | $1,129,000 | +20.4% | 18,651 | +3.0% | 0.01% | +25.0% |
Q1 2017 | $938,000 | +22.1% | 18,111 | +4.7% | 0.00% | +33.3% |
Q4 2016 | $768,000 | -1.0% | 17,301 | +6.2% | 0.00% | -25.0% |
Q3 2016 | $776,000 | -0.8% | 16,291 | -5.7% | 0.00% | 0.0% |
Q2 2016 | $782,000 | +16.7% | 17,281 | +5.9% | 0.00% | +33.3% |
Q1 2016 | $670,000 | +12.0% | 16,311 | +4.2% | 0.00% | 0.0% |
Q4 2015 | $598,000 | +22.5% | 15,661 | +5.5% | 0.00% | 0.0% |
Q3 2015 | $488,000 | -99.4% | 14,850 | -98.6% | 0.00% | -99.3% |
Q2 2015 | $76,210,000 | -2.2% | 1,089,926 | -4.2% | 0.42% | -2.3% |
Q1 2015 | $77,958,000 | -6.4% | 1,138,076 | +0.1% | 0.43% | -6.7% |
Q4 2014 | $83,323,000 | -2.9% | 1,136,886 | -4.9% | 0.46% | -6.3% |
Q3 2014 | $85,836,000 | -1.6% | 1,195,986 | -0.9% | 0.49% | +0.2% |
Q2 2014 | $87,228,000 | -2.9% | 1,206,475 | -1.2% | 0.49% | -11.7% |
Q1 2014 | $89,876,000 | -12.2% | 1,221,475 | -17.0% | 0.56% | -10.7% |
Q4 2013 | $102,365,000 | +35.3% | 1,471,825 | +27.8% | 0.62% | +30.3% |
Q3 2013 | $75,647,000 | +27.6% | 1,151,575 | +34.5% | 0.48% | +24.4% |
Q2 2013 | $59,307,000 | – | 856,175 | – | 0.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |